Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.
about
Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Anti-angiogenic therapy versus ...... II randomized clinical trials.
@en
type
label
Anti-angiogenic therapy versus ...... II randomized clinical trials.
@en
prefLabel
Anti-angiogenic therapy versus ...... II randomized clinical trials.
@en
P2093
P2860
P1476
Anti-angiogenic therapy versus ...... II randomized clinical trials.
@en
P2093
Kathleen N Moore
Katrina N Slaughter
Robert S Mannel
P2860
P2888
P356
10.1007/S11912-014-0412-2
P577
2014-11-01T00:00:00Z
P6179
1016763437